Significantly greater reduction from baseline seen in Wang bronchiolitis clinical score at day 3 for those aged 1 to 24 months ...
Ziresovir reduces respiratory syncytial virus (RSV) symptoms and viral load in infants, offering hope for an effective ...
China: In a promising development for pediatric care, a recent study has highlighted the efficacy of Ziresovir in treating ...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of ...
Current strategies to prevent severe RSV disease in infants include maternal vaccination with the RSV prefusion F vaccine ...
Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, "We are delighted that the results of the Phase 3 study DREAMS-2 for mazdutide in T2D will be presented in the form of a ...